Slide 1: Soligenix
(SOLIGENIX OTC QB: SNGX
Slide 2: Forward-Looking Statements
Forward-Looking Statements This presentation and the comments of our management related thereto contains forward-looking statements, which are generally statements that are not historical facts. Forward-looking statements can be identified by the words "expects," “anticipates,” "believes," "intends,
Slide 3: Company Highlights
Company Highlights + Diverse pipeline with nine (9) potential value drivers in development © Innovative products addressing high unmet medical needs © Experienced management and Board of Directors © Expertise in specialized development areas of GI, cancer supportive care and biodefense ° ° Potential
Slide 4: Development Candidates
Development Candidates BioTherapeutics ‘SGX942 Gmai Mucositle in Head 8: Neck Cancer FAST TRACK DESIGNATION Ph. 2 data 2H 2014" sox203 ORPHANIFAST TRACK DESIGNATION Ph. 2/3 data 1H 2015" Pediatric Crohn's Disease ao sox201 [DRUIPASTFRAERIDESIGNATIONNIN Pn. 20 start 1112014" Radiation Enteritis pees
Slide 5: Multiple Potential Value Drivers
Multiple Potential Value Drivers a) 1H: Oral Mucositis l 2H: P2 start in OM SGX942" (OM) IND Clearance Sex208 Designation Pediatric Crohn’s SGX201 Radiation Enteritis orsce: [ERR | Se =] 2H: Positive (2H: 1-year ThermoVax™ 6-mo stability data ‘stability data data released in ricin toxin: VeloThrax™
Slide 6: Experienced Management and Board of Directors
Experienced Management and Board of Directors Christopher J. ‘Schaber, MS, PhD President & CEO Robert Brey, PhD Chief Scientific Officer Kevin Horgan, MD Chief Medical Officer Joseph Warusz, CPA, MBA Acting Chief Financial Offi 24 years of experience Discovery Laboratories (COO) Acute Therapeutics (
Slide 7: BioTherapeutics
BioTherapeutics Targeted Approach to Treating Inflammation
Slide 8: BioTherapeutics Business Segment
BioTherapeutics Business Segment Our commercial target is inflammation } cose | dated ‘Supportive Cancer = Ent Oral BDP (orBe: Soligenix BioTherapeutics Segment Chronic HD Autoimmune | BDP. Pedi oh (Gl Inflammation) Disease OLIG
Slide 9: Oral Mucositis — Multi-Factorial Disease
Oral Mucositis — Multi-Factorial Disease Debilitating side effect of cancer chemotherapy and / or radiotherapy Massive ulceration of the mouth, tongue, soft palate and oropharynx Results in severe pain, inability to eat, reduced cancer treatment tolerance and significant increases in resource use an
Slide 10: Radiation-Induced Mucositis
Radiation-Induced Mucositis GOLD STANDARD Animal Model of Mucositis related to H&N Cancer + Decreased duration of mucositis by ~50% + Decreased peak severity from 3.4 to 3.0 50 ° rf £40 4 reduction § 30 P<.001 to) @ 20 ra x 10 Oo Vehicle SGX942 Oral Mucositis Induced in Hamsters by Fractionated Radi
Slide 11: Chemo-Induced Mucositis
Chemo-Induced Mucositis PROTECTS against chemotherapy damage PROTECTS ALL mucosal tissue Duration of Severe Oral Mucositis Clinical Endoscopy Score Ri 25: = 2 i 20 Day 4 Day 7 8 20 zo) —_— ——~- @ 2 5 reduction 8 3 2 p<.001 = | 8 a > 4 3 8 E 3 = Es 4 wa x 0 ro VEHICLE SGX942 3 Vehicle SGX942 Vehicle
Slide 12: SGX942 for Oral Mucositis
SGX942 for Oral Mucositis Phase 1 Clinical Trial Proprietary composition administered as 4-min IV infusion — short plasma half-life and rapid tissue penetration Phase 1 single and multiple ascending dose, double-blind, placebo-controlled study in 84 healthy volunteers Safe and well tolerated Pharmac
Slide 13: SGX942 — Other Development Targets
SGX942 — Other Development Targets Multiple potential targets in infectious disease and biodefense with opportunity for non-dilutive funding to support development Target Indication Potential Application (s) | Potential Funding — | Summary and Potential Next Steps Vaccine Adjuvant Biodefense; infect
Slide 14: Oral Beclomethasone 17,21-Dipropionate
Oral Beclomethasone 17,21-Dipropionate Overview SGX201, SGX203, orBec® and OrbeShield™ are all independent product opportunities based on our orally administered proprietary formulation technology with beclomethasone 17,21-dipropionate (BDP) Each enables potent, topical corticosteroid effect to trea
Slide 15: SGX203 for Pediatric Crohn's Disease
SGX203 for Pediatric Crohn’s Disease Two tablet proprietary formulation of immediate and delayed release BDP Overview Designed to treat inflammation throughout the Gl tract Positioned as a corticosteroid option with less toxicity than the current standard systemic steroid therapy — prednisone Over 1
Slide 16: SGX201 for Acute Radiation Enteritis
SGX201 for Acute Radiation Enteritis Proprietary time-release formulation of oral BDP Designed to block inflammatory component of radiation enteritis in Gl tract of cancer patients receiving pelvic radiation therapy Phase 1/2 open label, dose-ranging study completed in 16 subjects across five center
Slide 17: Vaccine/BioDefense
Vaccine/BioDefense Addressing Critical Concerns for Industry and Government
Slide 18: Vaccine/BioDefense Business Segment
Vaccine/BioDefense Business Segment Infectious Disease Vaccines ‘ThermoVax™ Heat Stabilization Platform BioDefense Vaccines RiVax™ Ricin Vaccine BioDefense Vaccines Soligenix Vaccine / BioDefense Division VeloThrax™ Anthrax Vaccine . OrbeShield™ Funded by Government (Oral BDP Therapeutic)
Slide 19: ThermoVax — Vaccine Thermostability Platform
ThermoVax™ — Vaccine Thermostability Platform Overview Market Opportunity Development Plan Dried vaccine with desirable physical and immunogenic properties Improved stability and shelf-life at temperatures exceeding 40°C Positive Proof of Concept achieved — 6 months stability data with no degradatio
Slide 20: RiVax — Ricin Toxin Vaccine
RiVax™ — Ricin Toxin Vaccine Produced as aluminum-adsorbed vaccine Efficacy against all routes of toxin exposure Non-human primate pilot efficacy studies demonstrated induction of neutralizing antibodies and protection against aerosol exposure Phase 1 studies demonstrated safety, induction of antibo
Slide 21: OrbeShield for GI ARS
OrbeShield™ for GI ARS Proprietary two tablet immediate and delayed release BDP formulation Multiple commercial scale cGMP batches manufactured with long-term controlled room temperature stability Statistically significant survival post radiation exposure versus controls in canine model of GI ARS 2-
Slide 22: SGX101 for Melioidosis
SGX101 for Melioidosis Overview Melioidosis is caused by Burkholderia pseudomallei (Bps) Frequently resistant to antibiotic treatment High mortality and relapse rate, despite prolonged therapy Exclusive Channel Collaboration with Intrexon Corporation Development of human monoclonal antibody (mAb) te
Slide 23: Significant WW Market Potential
Significant WW Market Potential Assumptions Oral Mucositis in H&N Cancer 90,000 Patients US 90,000 Patients EU Pediatric Crohn's Disease {80,000 Patients US £80,000 Patients EU Acute Radiation Enteritis in Colorectal cancer ‘60,000 Patients US 50,000 Patients EU Chronic GVHD Treatment 6,000 Patients
Slide 24: Investment Highlights
Investment Highlights + Diverse pipeline with nine (9) potential value drivers in development © Innovative products addressing high unmet medical needs © Experienced management and Board of Directors © Expertise in specialized development areas of Gl, cancer supportive care and biodefense ° ° Potent
Slide 25: Thank You
a - a THANK YOU